Sagimet Biosciences Inc. (SGMT) Research

Sagimet Biosciences Inc. is a biopharmaceutical company with drug candidates in clinical trials, specializing in developing therapies that target fatty acid synthase (FASN) inhibition. These treatments are engineered to combat medical conditions stemming from impaired lipid metabolism pathways. Its primary investigational compound, Denifanstat, is a FASN inhibitor currently being evaluated for nonalcoholic steatohepatitis (NASH) and acne. Additionally, Sagimet is advancing TVB-3567, another FASN inhibitor, which targets various forms of cancer. Founded in 2006, the company's main operations are located in San Mateo, California. It was formerly recognized as 3-V Biosciences, Inc. until it rebranded to Sagimet Biosciences Inc. in August 2019.

Market snapshot

Symbol
SGMT
Price
$6.68
Day change
+2.30%
Market cap
$217.6M
P/E ratio
-4.95x
52-week range
4.5-11.41
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$8.00

Recent news

  • Why Is Sagimet Biosciences Stock Trading Higher On Monday?

    Sagimet Biosciences Inc. (NASDAQ:SGMT) shares are surging on Monday, up 44% as the company announced strategic updates regarding its clinical trials.

Peer companies

  • Achieve Life Sciences, Inc. (ACHV)
  • Arcturus Therapeutics Holdings Inc. (ARCT)
  • Assembly Biosciences, Inc. (ASMB)
  • Atea Pharmaceuticals, Inc. (AVIR)
  • Foghorn Therapeutics Inc. (FHTX)
  • Humacyte, Inc. (HUMA)
  • Immuneering Corporation (IMRX)
  • Entrada Therapeutics, Inc. (TRDA)

Recent insider activity

  • SEIDENBERG BETH C — A-Award (39567 shares) on 2026-06-12
  • Hoelscher Paul W. — A-Award (39567 shares) on 2026-06-12
  • Jarrett Jennifer — A-Award (39567 shares) on 2026-06-12
  • GRAMMER ELIZABETH A — A-Award (39567 shares) on 2026-06-12
  • Kemble George — A-Award (39567 shares) on 2026-06-12

Open Sagimet Biosciences Inc. (SGMT) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.